ReviewStem cell research & therapy2026
Pathological mechanisms and therapeutic potential of MSC-Exos in ischemic stroke management.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cerebral ischemia-reperfusion injury (CIRI) represents a critical pathological challenge in the management of ischemic stroke, substantially limiting the clinical efficacy and success rates of neurosurgical interventions, brain tissue therapies, and cell transplantation strategies. The complex pathological mechanisms underlying CIRI, which include inflammatory responses, oxidative stress, ferroptosis, apoptosis, and blood-brain barrier disruption, significantly hinder neurological recovery. Mesenchymal stem cells-derived exosomes (MSC-Exos) have emerged as a promising acellular therapeutic strategy owing to their low immunogenicity, ability to cross the blood-brain barrier, and multi-target regulatory properties. This review compares MSC-Exos derived from multiple sources and summarises their mechanisms of action and therapeutic potential in CIRI. Despite ongoing challenges in standardisation and safety evaluation, accumulating preclinical evidence highlights their potential for future clinical translation and precision regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.